(Q43841267)

English

Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study

scientific article published in December 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

27 November 2017

Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study (English)

1 reference

Europe PubMed Central

27 November 2017

0 references

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

27 November 2017

author name string

S M Dursun

1

1 reference

Europe PubMed Central

27 November 2017

language of work or name

0 references

publication date

1 December 2001

1 reference

Europe PubMed Central

27 November 2017

Journal of Psychopharmacology

1 reference

Europe PubMed Central

27 November 2017

15

1 reference

Europe PubMed Central

27 November 2017

297-301

1 reference

Europe PubMed Central

27 November 2017

4

1 reference

Europe PubMed Central

27 November 2017

Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500409

21 January 2018

Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited.

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500409

21 January 2018

Clozapine augmentation: safety and efficacy

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500409

21 January 2018

A two-process theory of schizophrenia: evidence from studies in post-mortem brain

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500409

21 January 2018

Familial and developmental abnormalities of front lobe function and neurochemistry in schizophrenia.

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500409

21 January 2018

Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500409

21 January 2018

Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation.

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500409

21 January 2018

Clozapine plus lamotrigine in treatment-resistant schizophrenia.

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500409

21 January 2018

Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500409

21 January 2018

A pivotal role for glutamate in the pathogenesis of schizophrenia, and its cognitive dysfunction

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500409

21 January 2018

Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hypothesis.

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500409

21 January 2018

Amelioration of negative symptoms in schizophrenia by glycine.

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500409

21 January 2018

The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500409

21 January 2018

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500409

21 January 2018

Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500409

21 January 2018

Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia.

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500409

21 January 2018

Deficient NMDA-mediated glutamate release from synaptosomes of schizophrenics

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500409

21 January 2018

Comparison of glutamate and gamma-aminobutyric acid uptake binding sites in frontal and temporal lobes in schizophrenia.

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500409

21 January 2018

Functional anatomy of verbal fluency in people with schizophrenia and those at genetic risk

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500409

21 January 2018

The behavioral and neurochemical effects of phencyclidine in humans and animals: some implications for modeling psychosis

1 reference

https://api.crossref.org/works/10.1177%2F026988110101500409

21 January 2018

Identifiers

10.1177/026988110101500409

1 reference

Europe PubMed Central

27 November 2017

1 reference

Europe PubMed Central

27 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43841267&oldid=2103796765"